ARS Pharmaceuticals (SPRY) Receivables - Net (2024 - 2026)

ARS Pharmaceuticals (SPRY) has 3 years of Receivables - Net data on file, last reported at $28.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 208.09% year-over-year to $28.7 million; the trailing twelve-month figure through Mar 2026 stood at $28.7 million (up 208.09% YoY), and the FY2025 full-year result was $25.3 million, up 210.06% from the prior year.
• Receivables - Net rose to $28.7 million in Q1 2026, from $25.3 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $36.5 million in Q3 2025 to a low of $773000.0 in Q3 2024.
• A 3-year average of $19.1 million and a median of $25.1 million in 2025 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net jumped 4615.52% in 2025 and surged 208.09% in 2026, its largest moves.
• Tracing SPRY's Receivables - Net over 3 years: stood at $8.2 million in 2024, then jumped by 210.06% to $25.3 million in 2025, then increased by 13.08% to $28.7 million in 2026.
• Business Quant data shows SPRY's Receivables - Net at $28.7 million in Q1 2026, $25.3 million in Q4 2025, and $36.5 million in Q3 2025.